IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES AMONG LEISHMANIA SPECIES

利什曼原虫物种之间差异表达基因的鉴定

• 批准号: 8360069
• 负责人: ALISON M SHAKARIAN
• 金额: $ 1.81万
• 依托单位: UNIVERSITY OF RHODE ISLAND
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8360069
• 关键词: Africa; Area; Behavioral Research; Biomedical Research; Cloning; Collection; Complementary DNA; Contracts; DNA Sequence Analysis; Development; Disease; Funding; Gene Expression; Genes; Goals; Grant; India; Latin America; Leishmania; Leishmaniasis; Middle East; National Center for Research Resources; Parasites; Pharmaceutical Preparations; Pharmacotherapy; Principal Investigator; Proteins; Research; Research Infrastructure; Resources; Risk; Source; United States National Institutes of Health; Virulence; cost; human disease; novel

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The long term goal of this project is to identify and characterize differentially expressed genes in Leishmania that may be used as potential novel targets for the development of new drug therapies for the treatment of leishmaniasis. At least 12 million people in Africa, India and Latin America are infected with Leishmania, and 350 million are at risk. Moreover, the thousands of US troops currently deployed in endemic areas (i.e. the Middle East) are at significant risk for contracting the parasite and significant disease. It is poorly understood which genes and how many proteins are involved in the survival and virulence of the pathogenic species of Leishmania. We hypothesize that differences in the expression of genes among and between pathogenic and non pathogenic species should identify some of the genes that are critical to the survival and important to the virulence of these parasites. Thus, in the current study we will identify differentially expressed genes between pathogenic and nonpathogenic species of Leishmania by cDNAAFLP and subsequently characterize these genes by sub cloning the amplified fragments and subjecting them to DNA sequence and analyses. The characterization of genes differentially expressed between pathogenic and non pathogenic species is a first step in identifying potential novel targets for the development of nontoxic drugs to be used in the treatment of leishmaniasis, a devastating and potentially fatal collection of human diseases.

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 该项目的长期目标是确定和表征利什曼原虫差异表达的基因，这些基因可能被用作潜在的新靶点，用于开发治疗利什曼病的新药疗法。在非洲、印度和拉丁美洲，至少有1200万人感染了利什曼原虫，3.5亿人处于危险之中。此外，目前部署在流行地区(即中东)的数千名美军面临感染这种寄生虫和重大疾病的重大风险。利什曼原虫致病物种的生存和毒力与哪些基因和多少蛋白有关，目前还知之甚少。我们推测，致病和非致病物种之间以及致病和非致病物种之间基因表达的差异应该确定一些对这些寄生虫的生存和毒力至关重要的基因。因此，在本研究中，我们将利用cDNAAFLP技术鉴定利什曼原虫致病和非致病物种之间的差异表达基因，然后通过亚克隆扩增片段并对其进行DNA测序和分析来鉴定这些基因。确定致病和非致病物种之间差异表达基因的特征是确定潜在的新靶点的第一步，以开发用于治疗利什曼病的无毒药物。利什曼病是一种毁灭性的、可能致命的人类疾病。